Antibody-Functionalized Inorganic NPs: Mimicking Nature for Targeted Diagnosis and Therapy - Bioinspired Approaches for Human-Centric Technologies - page 23

toxic effects. Such opposite outcomes are likely related to the testing conditions that
differ not only for the type of nanoparticle used but also for the administered
amount and the administration routes (Chen et al. 2009 ; Lasagna-Reeves
et al. 2010 ).
In conclusion, any type of antibody-nanoparticle formulation requires a thor-
ough and definite analysis of the health impact. It is noteworthy that cellular studies
are only the first step of the safety evaluation that needs to move to animal testing to
assess the effects at the whole organism level. Furthermore, standard protocols and
toxicity assays should be internationally defined in order to achieve a comparable
overview of the literature data and an exhaustive comprehension of the safety
impact.
References
Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23:
1147-1157. doi: 10.1035/nbt1137
Aime S, Castelli DD, Crich SG, Gianolio E, Terreno E (2009) Pushing the sensitivity envelope of
lanthanide-based magnetic resonance imaging (MRI) contrast agents for molecular imaging
applications. Acc Chem Res 42:822-831. doi: 10.1021/ar800192p
Algar WR et al (2011) The controlled display of biomolecules on nanoparticles: a challenge suited
to bioorthogonal chemistry. Bioconjug Chem 22:825-858. doi: 10.1021/bc200065z
Alivisatos AP (1996) Semiconductor clusters, nanocrystals, and quantum dots. Science 271:
933-937
Amit AG, Mariuzza RA, Phillips SEV, Poljak RJ (1986) 3-Dimensional structure of an antigen-
antibody complex at 2.8-A resolution. Science 233:747-753. doi: 10.1126/science.2426778
Baca M, Presta LG, Oconnor SJ, Wells JA (1997) Antibody humanization using monovalent phage
display. J Biol Chem 272:10678-10684
Bartczak D, Sanchez-Elsner T, Louafi F, Millar TM, Kanaras AG (2011) Receptor-mediated
interactions between colloidal gold nanoparticles and human umbilical vein endothelial
cells. Small 7:388-394. doi: 10.1002/smll.201001816
Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D (2002) Pharmacokinetics and
biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 13:603-608.
doi: 10.1016/s0958-1669(02)00352-x
Bruggemann M, Taussig MJ (1997) Production of human antibody repertoires in transgenic mice.
Curr Opin Biotechnol 8:455-458. doi: 10.1016/s0958-1669(97)80068-7
Brust M, Walker M, Bethell D, Schiffrin DJ, Whyman R (1994) Synthesis of thiol-derivatized gold
nanoparticles in a 2-phase liquid-liquid system. J Chem Soc Chem Commun 7:801-802
Chan AC, Carter PJ (2010) Therapeutic antibodies for autoimmunity and inflammation. Nat Rev
Immunol 10:301-316. doi: 10.1038/nri2761
Chari RVJ (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem
Res 41:98-107. doi: 10.1021/ar700108g
Chen Y-S, Hung Y-C, Liau I, Huang G (2009) Assessment of the in vivo toxicity of gold
nanoparticles. Nanoscale Res Lett 4:858-864
Cherukuri P, Glazer ES, Curleya SA (2010) Targeted hyperthermia using metal nanoparticles.
Adv Drug Deliv Rev 62:339-345. doi: 10.1016/j.addr.2009.11.006
Chithrani BD, Chan WCW (2007) Elucidating the mechanism of cellular uptake and removal of
protein-coated gold nanoparticles of different sizes and shapes. Nano Lett 7:1542-1550.
doi: 10.1021/nl070363y